先看重点
在21 104名英国高血压成人中位随访5.2年,晚间服药组主要心血管事件发生率为3.4%,早间服药组为3.7%(风险比0.95;95% CI 0.83-1.10;p=0.53)。该试验为开放标签,部分事件靠参与者自报发现,且晚间组退出者更多。
证据类型
随机对照试验
解读依据
公开摘要
阅读重点
对照与不确定性
研究在问什么
此前有研究提示,睡前服用降压药可能比早晨服用更能保护心脏,但尚无定论。TIME研究想检验:把平常的降压药改到晚上服用,能否比早晨服用更好地降低主要心血管结局。
研究了谁,如何研究
TIME是在英国进行的前瞻性、务实、分散式、平行组、随机、开放标签、终点盲法的试验,纳入18岁及以上、至少服用一种降压药的高血压成人。2011年12月17日至2018年6月5日,21 104人按1:1随机分为早晨(0600-1000 h)或晚上(2000-0000 h)服用全部日常降压药。主要终点为血管性死亡,或因非致死性心肌梗死、非致死性卒中住院,按意向性分析人群的首次事件时间分析。终点来自参与者自报或英国国民健康服务(NHS)记录关联,并由对分组不知情的委员会判定。由英国心脏基金会资助,已在EudraCT和ISRCTN注册。
主要发现
以下为作者报告的结果。数字须连同人群和不确定性一起阅读。
- 121 104人被随机分组,晚间组10 503人,早间组10 601人(平均年龄65.1岁,57.5%为男性,中位随访5.2年)。
- 2晚间组362人(3.4%)发生主要终点事件(每100患者年0.69次),早间组390人(3.7%,每100患者年0.72次);未校正风险比0.95(95% CI 0.83-1.10;p=0.53),差异无统计学意义。
- 3未发现安全性问题。作者认为患者可以选择方便、且不良反应最小的时间服用日常药物。
局限与不确定性
- 1开放标签设计意味着参与者知道自己的服药时间;事件部分来自自报,不过判定委员会对分组不知情。
- 2退出全部随访的人数晚间组(529人,5.0%)多于早间组(318人,3.0%)。
- 3参与者90.5%为白人,平均年龄65.1岁,结果未必同样适用于其他人群。
- 4本文仅依据摘要解读,摘要未报告亚组效应。
对日常健康的启示
正在服用降压药的人,这项大型试验未发现早晨或晚上服药在保护心脏方面有优势,因此选择自己最容易记住、耐受最好的时间是合理的。改变服药时间或方式,应先与临床医生或药师商定。
如何联系自己的数据
家用袖带血压计可以显示一天内血压的变化,帮助医生判断服药时间是否合适。请在固定时间、相同姿势、用同一设备测量,并看多次读数的平均值,而不是单次数值。
如何理解这类证据
随机分组有助于因果推断,仍须检查分配、盲法、失访、随访时间和具体对照;标为随机试验不自动意味着高确定性。
作者的结构化摘要 English
以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。
Background
Studies have suggested that evening dosing with antihypertensive therapy might have better outcomes than morning dosing. The Treatment in Morning versus Evening (TIME) study aimed to investigate whether evening dosing of usual antihypertensive medication improves major cardiovascular outcomes compared with morning dosing in patients with hypertension.
Methods
The TIME study is a prospective, pragmatic, decentralised, parallel-group study in the UK, that recruited adults (aged ≥18 years) with hypertension and taking at least one antihypertensive medication. Eligible participants were randomly assigned (1:1), without restriction, stratification, or minimisation, to take all of their usual antihypertensive medications in either the morning (0600-1000 h) or in the evening (2000-0000 h). Participants were followed up for the composite primary endpoint of vascular death or hospitalisation for non-fatal myocardial infarction or non-fatal stroke. Endpoints were identified by participant report or record linkage to National Health Service datasets and were adjudicated by a committee masked to treatment allocation. The primary endpoint was assessed as the time to first occurrence of an event in the intention-to-treat population (ie, all participants randomly assigned to a treatment group). Safety was assessed in all participants who submitted at least one follow-up questionnaire. The study is registered with EudraCT (2011-001968-21) and ISRCTN (18157641), and is now complete.
Findings
Between Dec 17, 2011, and June 5, 2018, 24 610 individuals were screened and 21 104 were randomly assigned to evening (n=10 503) or morning (n=10 601) dosing groups. Mean age at study entry was 65·1 years (SD 9·3); 12 136 (57·5%) participants were men; 8968 (42·5%) were women; 19 101 (90·5%) were White; 98 (0·5%) were Black, African, Caribbean, or Black British (ethnicity was not reported by 1637 [7·8%] participants); and 2725 (13·0%) had a previous cardiovascular disease. By the end of study follow-up (March 31, 2021), median follow-up was 5·2 years (IQR 4·9-5·7), and 529 (5·0%) of 10 503 participants assigned to evening treatment and 318 (3·0%) of 10 601 assigned to morning treatment had withdrawn from all follow-up. A primary endpoint event occurred in 362 (3·4%) participants assigned to evening treatment (0·69 events [95% CI 0·62-0·76] per 100 patient-years) and 390 (3·7%) assigned to morning treatment (0·72 events [95% CI 0·65-0·79] per 100 patient-years; unadjusted hazard ratio 0·95 [95% CI 0·83-1·10]; p=0·53). No safety concerns were identified.
Interpretation
Evening dosing of usual antihypertensive medication was not different from morning dosing in terms of major cardiovascular outcomes. Patients can be advised that they can take their regular antihypertensive medications at a convenient time that minimises any undesirable effects.
Funding
British Heart Foundation.
来源与署名
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, Ford I, Rorie DA, Guthrie G, Grieve JWK, Pigazzani F, Rothwell PM, Young R, McConnachie A, Struthers AD, Lang CC, MacDonald TM, TIME Study Group.
Lancet (London, England) · 2022-10-11
DOI: 10.1016/s0140-6736(22)01786-x ↗PubMed · 36240838 ↗Europe PMC · 记录的开放许可: cc by ↗摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。
MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅
来源核验日期 2026-11-01
实用健康指南
放在一起读
昼夜活动节律紊乱与更高的死亡风险相关(109,365人)
在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。
Journal of the American Heart Association
五类运动都降低了静息血压,等长训练降幅最大
汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。
British Journal of Sports Medicine
盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降
在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。
The New England Journal of Medicine
智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤
在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。
The New England Journal of Medicine

